Compare Aurobindo Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DISHMAN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DISHMAN PHARMA AUROBINDO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 9.7 25.1 38.6% View Chart
P/BV x 1.8 3.3 53.5% View Chart
Dividend Yield % 0.6 0.7 88.5%  

Financials

 AUROBINDO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
DISHMAN PHARMA
Mar-16
AUROBINDO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs830374 221.7%   
Low Rs527129 408.9%   
Sales per share (Unadj.) Rs333.9197.8 168.8%  
Earnings per share (Unadj.) Rs40.421.2 190.3%  
Cash flow per share (Unadj.) Rs51.834.7 149.1%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.8 46.4%  
Book value per share (Unadj.) Rs237.1179.9 131.8%  
Shares outstanding (eoy) m585.9180.69 726.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.3 159.7%   
Avg P/E ratio x16.811.9 141.7%  
P/CF ratio (eoy) x13.17.2 180.9%  
Price / Book Value ratio x2.91.4 204.6%  
Dividend payout %6.29.4 65.7%   
Avg Mkt Cap Rs m397,56920,306 1,957.9%   
No. of employees `00017.90.8 2,153.8%   
Total wages/salary Rs m25,8495,355 482.7%   
Avg. sales/employee Rs Th10,956.919,252.7 56.9%   
Avg. wages/employee Rs Th1,447.76,459.5 22.4%   
Avg. net profit/employee Rs Th1,324.32,064.1 64.2%   
INCOME DATA
Net Sales Rs m195,63615,961 1,225.7%  
Other income Rs m1,553265 585.2%   
Total revenues Rs m197,18916,226 1,215.3%   
Gross profit Rs m39,5194,103 963.1%  
Depreciation Rs m6,6801,091 612.5%   
Interest Rs m2,626944 278.1%   
Profit before tax Rs m31,7672,334 1,361.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269624 1,165.6%   
Profit after tax Rs m23,6451,711 1,381.9%  
Gross profit margin %20.225.7 78.6%  
Effective tax rate %22.926.7 85.6%   
Net profit margin %12.110.7 112.7%  
BALANCE SHEET DATA
Current assets Rs m153,64511,018 1,394.5%   
Current liabilities Rs m120,4299,517 1,265.4%   
Net working cap to sales %17.09.4 180.5%  
Current ratio x1.31.2 110.2%  
Inventory Days Days135110 122.4%  
Debtors Days Days6435 182.8%  
Net fixed assets Rs m103,90916,304 637.3%   
Share capital Rs m586161 363.0%   
"Free" reserves Rs m138,32212,907 1,071.7%   
Net worth Rs m138,90814,516 957.0%   
Long term debt Rs m1,8004,189 43.0%   
Total assets Rs m264,54429,805 887.6%  
Interest coverage x13.13.5 377.3%   
Debt to equity ratio x00.3 4.5%  
Sales to assets ratio x0.70.5 138.1%   
Return on assets %9.98.9 111.5%  
Return on equity %17.011.8 144.4%  
Return on capital %23.817.5 136.0%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m97,3164,952 1,965.4%   
Fx outflow Rs m40,589697 5,825.1%   
Net fx Rs m56,7274,255 1,333.3%   
CASH FLOW
From Operations Rs m16,2202,786 582.1%  
From Investments Rs m-28,768-1,529 1,881.6%  
From Financial Activity Rs m19,191-941 -2,039.2%  
Net Cashflow Rs m6,656316 2,103.8%  

Share Holding

Indian Promoters % 54.1 61.4 88.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 3.7 214.9%  
FIIs % 27.7 12.7 218.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 22.1 46.2%  
Shareholders   69,601 46,261 150.5%  
Pledged promoter(s) holding % 8.6 35.8 23.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS